In this review:
Evinacumab for homozygous familial hypercholesterolaemia
Lipoprotein(a) reduction in CV disease
Inclisiran in heterozygous familial hypercholesterolaemia
CRP and lipoprotein(a)-associated CV risk in optimally treated high-risk vascular disease
Evolocumab and CV outcomes after recent MI
High-dose omega-3 fatty acids and MACE in high CV risk patients
Effect of SGLT-2 inhibitors on lipid parameters
Factors influencing bempedoic acid-mediated high-sensitivity CRP reductions
Bempedoic acid for dyslipidaemia in statin-intolerant patients
Icosapent ethyl for reducing ischaemic events after PCI
LDL cholesterol lowering for preventing major vascular events
Early vs. delayed primary prevention of CV disease by lipid lowering
Omega-3 fatty acids in elderly patients after MI
N-of-1 trial of a statin, placebo or no treatment to assess side effects
Long-term safety and efficacy of lomitapide in homozygous familial hypercholesterolaemia
Please login below to download this issue (PDF)